Second edition

22.qxd 3/10/08 10:01 AM Page 698
698 Medication and substance-induced disorders
Harper CG, Krill JJ. Brain atrophy in chronic alcoholic patients – a
quantitative pathological study. J Neurol Neurosurg Psychiatry
1985; 48:211–17.
Harper CG, Krill JJ, Holloway RL. Brain shrinkage in chronic
alcoholics: a pathological study. BMJ 1985; 290:501–4.
Harsch HH. Neuroleptic malignant syndrome: physiological and
laboratory findings in a series of nine cases. J Clin Psychiatry
1987; 48:328–33.
van Harten PN, Hoek HW, Matroos GE et al. Intermittent
neuroleptic treatment and risk of tardive dyskinesia: Curacao
extrapyramidal syndromes study III. Am J Psychiatry 1998;
155:565–7.
Hay DP, Hay L, Blackwell B et al. ECT and tardive dyskinesia.
J Geriatr Psychiatr Neurol 1990; 3:106–9.
Helenius J, Tatlisumak T, Soinne L et al. Marchiafava–Bignami
disease: two cases with favorable outcome. Eur J Neurol
2001; 8:269–72.
Hermesh H, Aizenburg D, Weizman A. A successful
electroconvulsive treatment of neuroleptic malignant
syndrome. Acta Psychiatr Scand 1987; 75:237–9.
Hormes JT, Filley CM, Rosenberg NL. Neurologic sequelae
of chronic solvent vapor abuse. Neurology 1986;
36:698–702.
Horn E, Lach B, Lapierre Y et al. Hypothalamic pathology in the
neuroleptic malignant syndrome. Am J Psychiatry 1988;
145:617–20.
Huang CC. Persistent tardive dyskinesia associated with
amoxapine therapy. Am J Psychiatry 1986; 143:1069–70.
Huang CC, Wang RI, Haegawa A et al. Reserpine and alphamethyldopa
in the treatment of tardive dyskinesia.
Psychopharmacology 1981; 73:359–62.
Ironside R, Bosanquet FD, McMenemy WH. Central demyelination
of the corpus callosum (Marchiafava–Bignami disease): with
report of a second case in Great Britain. Brain 1961;
84:212–30.
Itil T, Fink M. Anticholinergic drug-induced delirium: experimental
modification, quantitative EEG, and behavioral correlations.
J Nerv Ment Dis 1966; 143:492–507.
Ivanovitch M, Glantz R, Bone RC et al. Respiratory dyskinesia
presenting as acute respiratory distress. Chest 1993;
103:314–16.
Jensen GB, Pakkenberg B. Do alcoholics drink their neurons away?
Lancet 1993; 342:1201–4.
Jernigan TL, Butters N, Ditraglia G et al. Reduced cerebral grey
matter in alcoholics using MRI. Alcoholism Clin Exp Res 1991;
15:418–27.
Jeste DV, Potkin SG, Sinha S et al. Tardive dyskinesia – reversible
and persistent. Arch Gen Psychiatry 1979; 36:585–90.
Johkura K, Naito M, Naka T. Cortical involvement in
Marchiafava–Bignami disease. AJNR 2005; 26:670–3.
Jones EM, Dawson A. Neuroleptic malignant syndrome: a case
report with post-mortem brain and muscle pathology. J Neurol
Neurosurg Psychiatry 1989; 52:1006–9.
Kamaki M, Kawamura M, Moriya H et al. ‘Crossed homonymous
hemianopia’ and a ‘crossed left hemispatial neglect’ in a case
of Marchiafava–Bignami disease. J Neurol Neurosurg
Psychiatry 1993; 56:1027–32.
Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk
factors, 1959–1979. Arch Gen Psychiatry 1982; 39:473–81.
Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence,
incidence and risk factors. J Clin Psychopharmacol 1988;
8:52S–56S.
Kang UJ, Burke RE, Fahn S. Natural history and treatment of
tardive dystonia. Mov Disord 1986; 1:193–208.
Kawamura M, Shiota J, Yagishita T et al. Marchiafava–Bignami
disease: computed tomographic scan and magnetic resonance
imaging. Ann Neurol 1985; 18:103–4.
Keck PE, Pope HG, McElroy SL. Frequency and presentation of
neuroleptic malignant syndrome: a prospective study. Am J
Psychiatry 1987; 144:1344–6.
Kellam AMP. Neuroleptic malignant syndrome, so-called. A survey
of the world literature. Br J Psychiatry 1987; 150:752–9.
Kellam AMP. The (frequently) neuroleptic malignant syndrome.
Br J Psychiatry 1990; 157:169–73.
Kennedy PF. Chorea and phenothiazines. Br J Psychiatry 1969;
115:103–4.
Keyser DL, Rodnitzky RL. Neuroleptic malignant syndrome in
Parkinson’s disease after withdrawal or alteration of
dopaminergic therapy. Arch Int Med 1991; 151:794–6.
Khan JA. Occasional notes: atropine poisoning in Hawthorne’s The
Scarlet Letter. N Engl J Med 1984; 311:414–17.
Kiriakakis V, Bhatia K, Quinn NP et al. The natural history of
tardive dystonia: a long-term follow-up study of 107 cases.
Brain 1998; 121:2053–66.
Kirkpatrick B, Alphs L, Buchanen RW. The concept of
supersensitivity psychosis. J Nerv Ment Dis 1992; 180:265.
Klawans HL, Rubovits R. Effect of cholinergic and anticholinergic
agents on tardive dyskinesia. J Neurol Neurosurg Psychiatry
1974; 37:941–7.
Knox JW, Nelson JR. Permanent encephalopathy from toluene
inhalation. N Engl J Med 1966; 275:1494–6.
Koch M, Chandragiri S, Rizvi S et al. Catatonic signs in neuroleptic
malignant syndrome. Compr Psychiatry 2000; 41:73–5.
Koeppen AH, Barron KD. Marchiafava–Bignami disease. Neurology
1978; 28:290–4.
Kontaxakis VP, Havaki-Kontaxaki BJ, Pappa DA et al. Neuroleptic
malignant syndrome after addition of paroxetine to
olanzapine. J Clin Psychopharmacol 2003; 23:671–2.
Kornfeld M, Moser AB, Moser HW et al. Solvent vapor abuse
leukoencephalopathy. Comparison to adrenoleukodystrophy.
J Neuropathol Exp Neurol 1994; 53:389–98.
Korobkin R, Asbury AK, Sumner AJ et al. Glue-sniffing neuropathy.
Arch Neurol 1975; 32:158–62.
Kraepelin E. Dementia praecox and paraphrenia. Huntington, NY:
Robert E. Krieger, 1971.
Krill JJ, Halliday GM, Svoboda MD et al. The cerebral cortex is
damaged in chronic alcoholics. Neuroscience 1997;
79:983–98.
Lang AE. Withdrawal akathisia: case reports and a proposed
classification of chronic akathisia. Mov Disord 1994;
9:188–92.
Lattanzi L, Mungai F, Romano A et al. Subcutaneous apomorphine
for neuroleptic malignant syndrome. Am J Psychiatry 2006;
163:1450–1.